Combined Versus Separate Sessions of Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography for the Diagnosis and Management of Pancreatic Ductal Adenocarcinoma with Biliary Obstruction
Background A single-procedure session combining EUS and ERCP (EUS/ERCP) for tissue diagnosis and biliary decompression for pancreatic duct adenocarcinoma (PDAC) is technically feasible. While EUS/ERCP may offer expedience and convenience over an approach of separate procedures sessions, the technica...
Gespeichert in:
Veröffentlicht in: | Digestive diseases and sciences 2021-08, Vol.66 (8), p.2786-2794 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background
A single-procedure session combining EUS and ERCP (EUS/ERCP) for tissue diagnosis and biliary decompression for pancreatic duct adenocarcinoma (PDAC) is technically feasible. While EUS/ERCP may offer expedience and convenience over an approach of separate procedures sessions, the technical success and risk for complications of a combined approach is unclear.
Aims
Compare the effectiveness and safety of EUS/ERCP versus separate session approaches for PDAC.
Methods
Study patients (2010–2015) were identified within our ERCP database. Patients were analyzed in three groups based on approach: Group A: Single-session EUS-FNA and ERCP (EUS/ERCP), Group B: EUS-FNA followed by separate, subsequent ERCP (EUS then ERCP), and Group C: ERCP with/without separate EUS (ERCP ± EUS). Rates of technical success, number of procedures, complications, and time to initiation of PDAC therapies were compared between groups.
Results
Two hundred patients met study criteria. EUS/ERCP approach (Group A) had a longer index procedure duration (median 66 min,
p
= 0.023). No differences were observed between Group A versus sequential procedure approaches (Groups B and C) for complications (
p
= 0.109) and success of EUS-FNA (
p
= 0.711) and ERCP (
p
= 0.109). Subgroup analysis (> 2 months of follow-up, not referred to hospice,
n
= 126) was performed. No differences were observed for stent failure (
p
= 0.307) or need for subsequent procedures (
p
= 0.220). EUS/ERCP (Group A) was associated with a shorter time to initiation of PDAC therapies (mean, 25.2 vs 42.7 days,
p
= 0.046).
Conclusions
EUS/ERCP approach has comparable rates of success and complications compared to separate, sequential approaches. An EUS/ERCP approach equates to shorter time interval to initiation of PDAC therapies. |
---|---|
ISSN: | 0163-2116 1573-2568 |
DOI: | 10.1007/s10620-020-06564-0 |